Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-4430 and Midazolam DDI Study
NCT02233244Phase 1Completed
- Sponsor
- Celtaxsys, Inc.
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acebilustat in cystic fibrosis (CF), sponsored by Celtaxsys, Inc. Primary endpoints: Maximum Plasma Concentration at 10 days and Area Under the Curve at 10 days. Started Sep 2014; status: completed.
02
Drugs
acebilustat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02233244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02233244.